

# 12/D  
Jorga  
3/18/03

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson, et al.

Group Art Unit: 1644

Application No. 09/758,173

Examiner: Phillip Gambel

Filed: January 12, 2001

Title: HUMAN B7.1 SPECIFIC PRIMATIZED ANTIBODIES AND  
TRANSFECTOMAS EXPRESSING SAID ANTIBODIESRECEIVED  
MAR 17 2003  
TECH CENTER 1600/2900

\* \* \* \* \*

AMENDMENT AND REPLYHon. Commissioner of Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed on October 11, 2002, please consider the following amendment and remarks.

IN THE CLAIMS

Please cancel claim 22, amend claims 21, 23, 24, 32, and 33, and add new claim 37, as shown below:

D1 21. (Amended) A method of treating B cell lymphoma comprising administering a therapeutically effective amount of an anti-B7.1 antibody.

✓  
22. canceled.

D2 23. (Amended) The method of claim 21 wherein said antibody binds the same epitope as an anti-B7.1 antibody selected from the group consisting of 7C10, which has the variable sequences shown in Figures 8a and 8b (amino acid sequences of SEQ ID NOs. 1-2 and 3-4 respectively); 7B6, which has the variable sequences shown in Figures 9a and 9b (amino acid sequences of SEQ ID NOs. 5-6 and 7-8 respectively); and 16C10, which has the